Compare BNZI & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNZI | CDT |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | United States |
| Employees | 34 | 4 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 5.9M |
| IPO Year | N/A | N/A |
| Metric | BNZI | CDT |
|---|---|---|
| Price | $3.49 | $0.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $24.00 | N/A |
| AVG Volume (30 Days) | 1.7M | ★ 2.5M |
| Earning Date | 05-14-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.28 | N/A |
| Revenue Next Year | $0.92 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.37 |
| 52 Week High | $8.10 | $11.00 |
| Indicator | BNZI | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 34.66 |
| Support Level | $0.84 | $0.49 |
| Resistance Level | $3.51 | $1.22 |
| Average True Range (ATR) | 1.06 | 0.35 |
| MACD | -0.22 | -0.03 |
| Stochastic Oscillator | 5.56 | 4.97 |
Banzai International Inc is a Software as a Service (SaaS) company operating in the marketing technology (MarTech) industry. The group provides customers with tools to help them market and sell with greater efficiency and impact. Its customers include Amazon, Dell, Salesforce, Aflac, Thermo Fisher Scientific, RBC Wealth Management, Fitch Group, and many other brands. The Company has three reportable operating segments: Banzai Operating Co, Inc., OpenReel, and Vidello. Its segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions, including video production and editing, for businesses of all sizes. Geographically, it operates in the Americas, Europe, the Middle East and Africa (EMEA), and the Asia Pacific.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.